Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.
- NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_assertion description "[Topoisomerase II (TOP2) targeting drugs like doxorubicin and etoposide are frontline chemotherapeutics for a wide variety of solid and hematological malignancies, including breast and ovarian adenocarcinomas, lung cancers, soft tissue sarcomas, leukemias and lymphomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.
- NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_assertion evidence source_evidence_literature NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.
- NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_assertion SIO_000772 22900064 NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.
- NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_assertion wasDerivedFrom befree-20150227 NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.
- NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_assertion wasGeneratedBy ECO_0000203 NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.
- befree-20150227 importedOn "2015-02-27" NP749091.RAdCN8uv5H9xOYBgpgl2yMEA3tfA6Tp86_cjCkm2SAWfA130_provenance.